Published in J Diabetes Res on February 15, 2015
Relevance of TNF-α in the context of other inflammatory cytokines in the progression of diabetic nephropathy. Kidney Int (2015) 0.82
The protective effects of oral low-dose quercetin on diabetic nephropathy in hypercholesterolemic mice. Front Physiol (2015) 0.79
Potential Role of Serum and Urinary Biomarkers in Diagnosis and Prognosis of Diabetic Nephropathy. Can J Kidney Health Dis (2017) 0.76
PECAM-1 Leu125Val (rs688) Polymorphism and Diabetic Nephropathy in Caucasians with Type 2 Diabetes Mellitus. Anal Cell Pathol (Amst) (2016) 0.75
Analysis of the IL-10, IL-12, and TNF-α Gene Polymorphisms in Patients With Vesicoureteral Reflux Among the Southeast Iranian Population. Nephrourol Mon (2016) 0.75
Toll-like receptor 2 agonist exacerbates renal injury in diabetic mice. Exp Ther Med (2017) 0.75
Developing Treatments for Chronic Kidney Disease in the 21st Century. Semin Nephrol (2016) 0.75
Positioning of Tacrolimus for the Treatment of Diabetic Nephropathy Based on Computational Network Analysis. PLoS One (2017) 0.75
LincRNA-Gm4419 knockdown ameliorates NF-κB/NLRP3 inflammasome-mediated inflammation in diabetic nephropathy. Cell Death Dis (2017) 0.75
Serum Interleukin-18 and Its Gene Haplotypes Profile as Predictors in Patients with Diabetic Nephropathy. Open Access Maced J Med Sci (2016) 0.75
Angiotensin-(1-7) Downregulates Diabetes-Induced cGMP Phosphodiesterase Activation in Rat Corpus Cavernosum. Biomed Res Int (2017) 0.75
The association between interleukin-19 concentration and diabetic nephropathy. BMC Nephrol (2017) 0.75
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA (2001) 15.85
Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature (1995) 10.89
Is type II diabetes mellitus a disease of the innate immune system? Diabetologia (1998) 5.43
Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care (2004) 4.88
NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia (1997) 4.88
Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet (1999) 4.07
Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol (2011) 3.68
The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol (2008) 3.64
Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J Immunol (1988) 3.64
End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis (1999) 3.00
Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. Kidney Int (2007) 2.98
Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes (2006) 2.85
Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest (2001) 2.84
Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med (1990) 2.79
Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest (2002) 2.65
Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int (2004) 2.29
Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol (2005) 2.23
Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int (2006) 2.22
Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol (2005) 2.18
Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int (2014) 2.09
The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis (2008) 2.09
The epidemiology of chronic kidney disease. Kidney Int Suppl (2005) 2.01
The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet (2005) 1.95
Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes (2003) 1.91
Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond) (2005) 1.90
Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism (2003) 1.90
Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol (2006) 1.89
Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation (1998) 1.87
Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol (1999) 1.86
Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci (2000) 1.85
NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant (2004) 1.78
Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int (1991) 1.73
Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) (2013) 1.69
Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep (2003) 1.67
The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol (2010) 1.65
IL-12-induced IFN-gamma is dependent on caspase-1 processing of the IL-18 precursor. J Clin Invest (1999) 1.64
Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol (2005) 1.63
Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int (2000) 1.62
Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery (1991) 1.62
Macrophage accumulation in human progressive diabetic nephropathy. Nephrology (Carlton) (2006) 1.51
Tumor necrosis factor induces glomerular damage in the rabbit. Am J Pathol (1989) 1.51
Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis (2003) 1.50
New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest (2004) 1.46
Reduction of macroalbuminuria with pentoxifylline in diabetic nephropathy. Report of three cases. Diabetes Care (1998) 1.41
Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol (2005) 1.41
Stimulated kidney tubular epithelial cells express membrane associated and secreted TNF alpha. Kidney Int (1991) 1.35
Role of inflammation in diabetic complications. Nephrol Dial Transplant (2005) 1.33
Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1998) 1.32
Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med (2001) 1.30
Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol (2006) 1.29
Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol (2004) 1.28
Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes (2000) 1.26
Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens (2006) 1.26
Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappaB and AP-1. Am J Physiol Lung Cell Mol Physiol (2002) 1.25
Inflammation and diabetic nephropathy. Curr Diab Rep (2006) 1.23
Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler Thromb Vasc Biol (2003) 1.22
TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol (1998) 1.21
Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol (2007) 1.17
Defining human diabetic nephropathy on the molecular level: integration of transcriptomic profiles with biological knowledge. Rev Endocr Metab Disord (2008) 1.16
Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat renal mesangial cells. Biochem Biophys Res Commun (1989) 1.13
Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy. Clin Exp Immunol (2007) 1.12
Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol (2002) 1.09
Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int Suppl (2005) 1.09
Upregulated IL-18 expression in type 2 diabetic subjects with nephropathy: TGF-beta1 enhanced IL-18 expression in human renal proximal tubular epithelial cells. Diabetes Res Clin Pract (2008) 1.09
Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy (2005) 1.08
Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol Dial Transplant (2006) 1.07
Angiotensin II stimulates interleukin-6 release from cultured mouse mesangial cells. J Am Soc Nephrol (1995) 1.06
In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes (1995) 1.05
Raised serum sialic acid concentration in NIDDM patients with and without diabetic nephropathy. Diabetes Care (1996) 1.05
Role of macrophages in the pathogenesis of diabetic nephropathy. Contrib Nephrol (2001) 1.05
Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. Am J Physiol Renal Physiol (2011) 1.04
Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: from glucose metabolism to neurodegeneration. Exp Diabesity Res (2003) 1.04
Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol (2005) 1.03
Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab (2006) 1.02
Role of tumor necrosis factor alpha, interleukin-1beta, and interleukin-6 in a mouse model of group B streptococcal arthritis. Infect Immun (1999) 1.02
Tumor necrosis factor stimulates prostaglandin production and cyclic AMP levels in rat cultured mesangial cells. FEBS Lett (1988) 1.02
Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care (2005) 1.02
Inflammatory cells in renal injury and repair. Semin Nephrol (2007) 1.02
Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis (1999) 1.01
Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis. Arthritis Rheum (2004) 1.01
Role of tumor necrosis factor-alpha in the pathogenesis of glomerular diseases. Kidney Int Suppl (1993) 1.01
Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol (2004) 0.99
Regulation of renal proximal tubular epithelial cell hyaluronan generation: implications for diabetic nephropathy. Kidney Int (2001) 0.99
Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. Diabetes Care (2003) 0.98
Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J Am Soc Nephrol (2014) 0.97
Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabet Med (2004) 0.97
Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine (1995) 0.96
Increased levels of C-reactive protein in noncontrolled type II diabetic subjects. J Diabetes Complications (2000) 0.96
Cytokines and growth factors in renal disease. Nephrol Dial Transplant (1995) 0.96
Selective regulation of intercellular adhesion molecule-1 expression by interleukin-18 and interleukin-12 on human monocytes. Immunology (2003) 0.96
The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production. Immunology (1998) 0.93
Cytokine modulation by PX differently affects specific acute phase proteins during sepsis in rats. Am J Physiol (1998) 0.93
Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. Am J Kidney Dis (2003) 0.92
Lymphocytes promote albuminuria, but not renal dysfunction or histological damage in a mouse model of diabetic renal injury. Diabetologia (2010) 0.92
Differential effect of IL-18 on endothelial cell apoptosis mediated by TNF-alpha and Fas (CD95). Cytokine (2003) 0.91
Interleukin-6: an autocrine regulator of mesangial cell growth. Kidney Int (1992) 0.91
Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol (2004) 0.88
Diabetes: treating diabetic nephropathy-still an unresolved issue. Nat Rev Endocrinol (2012) 0.88